The Effects of Pyridostigmine on Dysphagia in Patients With Multiple Sclerosis

Not Applicable

Recruiting

Conditions: Condition 1: Multiple Sclerosis. Condition 2: Dysphagia.
Multiple sclerosis
R13.1
Dysphagia

Registration Number: IRCT20090429001859N11

Lead Sponsor: Tehran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 48

Inclusion Criteria

A diagnosis of multiple sclerosis is made by a neurologist specialized in multiple sclerosis, based on the 2017 McDonald criteria, and the patient is receiving treatment for multiple sclerosis.
After explaining the goals and methods of the study and all the sections of the informed consent form, the patient is willing towards participation and cooperation.
The patient has a DYMUS score of at least 3, based on the persian version of the questionnaire.

Exclusion Criteria

Any comorbidity due to previous neurological disorders, e.g. previous cerebrovascular accidents.
Other neurological disorders
A history of relapse (if MS type is relapsing-remitting) in the previous 3 months.
An Expanded Disability Status Scale (EDSS) score above 7.5.
Currently being under treatment with pyridostigmine for any reasons.
A history of hypersensitivity to anticholinesterase inhibitors or any of the compounds found in our placebo.
The patient has mechanical obstruction in intestinal or urinary tract.
The patient is currently pregnant or breastfeeding.
Dysphagia caused by other disorders than MS.
Having a decision to start any other treatment for dysphagia in time of the study, or having started in the last 3 months.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patient's score based on the Persian version of DYMUS questionnaire. Timepoint: In the beginning of the study, and after 1 and 3 weeks of intervention. Method of measurement: Persian version of DYMUS questionnaire.

Secondary Outcome Measures

Name	Time	Method
Patient's score based on the Persian version of EAT-10 questionnaire. Timepoint: In the beginning of the study, and after 1 and 3 weeks of intervention. Method of measurement: Persian version of EAT-10 questionnaire.;Patient's score based on the Persian version of SWAL-QOL questionnaire. Timepoint: In the beginning of the study, and after 3 weeks of intervention. Method of measurement: Persian version of SWAL-QOL questionnaire.